At IDWeek 2026, IDSA and HIVMA leaders and clinician advocates outline how stories, relationships, and bipartisan outreach shape ID and HIV policy.
|Articles|December 10, 2012
How Much For An MRI? $500? $5,000? A Reporter Struggles To Find Out
Advertisement
Massachusetts is launching a sweeping plan to hold down health care costs. A new law is partly designed to get patients to help drive down prices by shopping for medical care.
So when I had a series of migraines over the summer, I decided this was an opportunity to be an engaged, savvy patient.
Read the full story:
Source: Kaiser Health News (in collaboration with WBUR and NPR)
Advertisement
Related to this article
As CKCC nears its sunset, kidney care leaders urge CMS to preserve a dedicated, nephrologist-led accountable care model for advanced kidney disease.
Legal and clinical experts examined the US medical aid in dying framework, its limits, and ethical debates.
Jennifer Flythe, MD, MPH, discusses individualizing dialysis volume management and why guideline-directed therapy use lags in advanced CKD.
Povetacicept reduced proteinuria by 52% vs 4.3% with placebo at week 36 in adults with IgA nephropathy in the phase 3 RAINIER trial’s interim analysis.
Outpatient dialysis for unfunded patients with ESKD cut ED reliance and costs, while church-based CKD screening improved blood pressure.
Asian expert consensus updates mantle cell lymphoma treatment guidelines, highlighting uneven BTK inhibitor, ibrutinib and CAR T-cell access across Asia.
At ASN Kidney Week 2026, nephrologists said value-based kidney models improved dialysis starts, but payment cuts and MA growth are pushing practices out.
Advertisement
Advertisement
Trending on AJMC
1
Awareness Gaps Drive Narcolepsy, IH Delays: Logan Schneider, MD
2
Nephrologists Weigh Wins, Losses From 5 Years of Value-Based Kidney Care
3
Merck, Moderna Cancer Vaccine Cuts Melanoma Recurrence Risk by 42%
4
Povetacicept Cuts Proteinuria by 52% in IgA Nephropathy at Week 36
5